The Hindu Business Line : Lupin signs deal with Cornerstone to promote Suprax in US

Lupin's sales-force in the US has been promoting this drug to paediatricians and the new deal seeks to expand this coverage to primary care physicians as well.

The deal was inked with Lupin Pharmaceuticals Inc (LPI), a wholly owned subsidiary of Lupin. Cornerstone's sales-force will co-promote Suprax, a Lupin release issued here on Thursday said.

Cornerstone BioPharma is a non-traditional speciality pharmaceutical company focused in the pain, wound healing and respiratory markets. It's primary focus for Suprax will be to promote the product to primary care physicians, who were not covered by Lupin's sales-force, the note said. The deal is also significant since Lupin has been incurring promotional costs on account of this product, a pharma analyst said.

Suprax was approved in 2004 and was promoted by LPI's paediatric-focused sales-force, the note said. The partnership represents a significant expansion in the scope of physician coverage for Suprax in the $1.2-billion US oral suspension anti-infective market.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Reliance Info shares allotted at discount to 3 more companies

Tata Chem raises $150 m via FCCBs

Illegal routing dispute: HC asks BSNL to clarify stand on arbitration

Get tough with polluting units, Reddy tells PCB

Dabur buys 3 Balsara group cos for Rs 143 cr

Celebrity acquires Span Eicher Design for Rs 5 crore

Lupin signs deal with Cornerstone to promote Suprax in US

Indian Immunologicals forms joint venture with US company for livestock breeding

Videocon group eyes $1-b global sales

GCC achieves Rs 112-crore sales turnover